KGS vs KOD: How Kodiak Gas Services and Kodiak Sciences Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KGS and KOD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KGS and KOD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Kodiak Gas Services, Inc. owns and operates contract compression infrastructure for oil and gas producers and midstream operators, primarily in the Permian Basin and Eagle Ford. Customers pay monthly fees for Kodiak to install, run, and maintain large-horsepower compression packages that push associated natural gas through gathering systems, so revenue tracks installed horsepower under contract rather than the commodity price directly. The 2024 all-equity acquisition of CSI Compressco (~$854 million) created the industry's largest fleet and added gas treating, cooling, and aftermarket services, and the fleet stood at ~4.39 million revenue-generating horsepower at ~98% utilization in Q1 2026.

Full KGS guide

Kodiak Sciences is a Palo Alto based biotechnology company developing therapies for high-prevalence retinal diseases such as diabetic retinopathy, wet age-related macular degeneration (wet AMD), and macular edema. Its programs are built on an antibody biopolymer conjugate (ABC) platform intended to extend how long a single injection lasts in the eye. The lead candidate, tarcocimab tedromer (branded Zenkuda), delivered positive Phase 3 GLOW2 data in diabetic retinopathy in early 2026, while additional Phase 3 studies (DAYBREAK in wet AMD with KSI-501, and PEAK and PINNACLE for KSI-101 in macular edema secondary to inflammation) are reading out into 2027.

Full KOD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• KGS drivers: Distributed power for data centers; Contracted compression as the cash engine.
• KOD drivers: Multi-indication Phase 3 pipeline; Durability-focused ABC platform.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The power expansion is capital intensive and unproven at scale for Kodiak: growth capex is guided at ~$645 million to ~$775 million for 2026, and turbine and engine delivery slots stretch into 2029, so contracted megawatts and actual cash flow can arrive years apart. For KOD, as a pre-revenue clinical-stage biotech, Kodiak is exposed to binary trial risk, and a single failed Phase 3 readout can move the stock sharply, as the 2021 wet AMD failure demonstrated.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KGS if you believe its drivers more; KOD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KGS and KOD guides.

KGS. The headline P/E is misleading in both directions: net income of ~$66 million on ~$1.32 billion of revenue reflects heavy depreciation on a compression fleet and interest on acquisition debt, while adjusted EBITDA of ~$820 million to ~$860 million and discretionary cash flow of ~$520 million to ~$570 million are the numbers management and most analysts anchor on. Fleet utilization at ~98% and a ~70.6% compression gross margin show the base business running near capacity. Q2 2026 results are due August 6, 2026, and the market's focus is on power contract announcements rather than the compression line.

KOD. Kodiak has no product revenue and posts steady net losses, so traditional earnings multiples do not apply and valuation reflects pipeline expectations. Cash of roughly $170 million against a quarterly burn near $58 million supports operations into 2027, meaning further financing could be needed. The market capitalization near $1.3 billion effectively prices in the probability-weighted value of its Phase 3 programs.

Headline figures (approximate, August 2026): KGS shows revenue (ttm) ~$1.32B, q1 2026 revenue ~$346M (+5% YoY), q1 2026 adjusted ebitda ~$190M (~55% margin), 2026 adjusted ebitda guidance ~$820M-$860M; KOD shows revenue (ttm) ~$0 (no approved products), net loss (q1 2026) ~$58M, r&d expense (q1 2026) ~$49M, cash & equivalents (mar 2026) ~$170M.

KGS and KOD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KGS and KOD exposure against your real portfolio. It is not an investment adviser.